SGN-35 for Skin Lymphomas

Recruiting in Palo Alto (17 mi)

Overseen byAuris O Huen, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The goal of this clinical research study is to learn if SGN-35 (brentuximab vedotin) can help to control ALCL, LyP or MF in patients with at least 1 of the 3 skin lymphomas. The safety of the study drug will also be studied.

Research Team

Auris O Huen, MD

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

Adults with certain skin lymphomas (ALCL, LyP, or MF) that are CD30 positive and have not responded to previous treatments like radiation therapy or chemotherapy. They must be in good enough health for systemic therapy as judged by the doctor, not pregnant, willing to use contraception, and able to follow study procedures.

Inclusion Criteria

I can take care of myself but might not be able to do heavy physical work.

I can attend all required study visits for tests and treatment management.

I am not pregnant and agree to use birth control during the study.

See 10 more

Exclusion Criteria

I do not have any serious health conditions that would interfere with treatment.

I have dementia or changes in my mental status.

I do not have severe infections.

See 6 more

Treatment Details

Interventions

SGN-35 (Monoclonal Antibodies)

Trial OverviewThe trial is testing SGN-35 (brentuximab vedotin) for its effectiveness in controlling three types of skin lymphomas: ALCL, LyP, and MF. It also aims to evaluate the safety profile of this drug in patients who have these conditions.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: SGN-35Experimental Treatment1 Intervention

1.8 mg/kg intravenously Day 1 of 21-day cycle.